Monique's breast cancer journey
Follow Monique on her individual cancer pathway
1Ren W, Chen M, Qiao Y, Zhao F. Global guidelines for breast cancer screening: A systematic review. Breast. 2022 Aug;64:85-99. doi: 10.1016/j.breast.2022.04.003. Epub 2022 Apr 19. PMID: 35636342; PMCID: PMC9142711. World Cancer Research Fund International, referring to data from 2020, wcrf.org/cancer-trends/worldwide-cancer-data.
2American Cancer Society Statistics show that about 13% (about 1 in 8) of U.S. women are going to develop invasive breast cancer in the course of their life, www.breastcancer.org/facts-statistics (July 2023).
3MAMMOMAT B.brilliant is not commercially available in all countries. Due to regulatory reasons its future availability cannot be guaranteed.
4CE marked. 510(k) pending. Not available for sale in all markets.
5HyperSight is an optional feature.
6Available only on TrueBeam, Edge, and VitalBeam systems equipped with Motion Management Interface (MMI).
VARIAN, ARIA CORE, TRUEBEAM, HYPERSIGHT, IDENTIFY , NOONA, ECLIPSE, RAPIDARC, MCO ISODOSE LINE DRAGGING, and RAPIDPLAN are trademarks of Varian Medical Systems, Inc., pending or registered U.S. Pat. & Tm. Off. All other trademarks are property of their respective owners.
The products/features mentioned herein are not commercially available in all countries. Their future availability cannot be guaranteed.